Many of the targets identified in our study have previously been identified on addition of ALK TKIs to NB cells, such as STAT3, CRK, FOXO3 and PTPN11 (Emdal et al, 2018; Van den Eynden et al, 2018). This evidence concerns the gene ALK and neuroblastoma.